Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts

Journal of Thoracic and Cardiovascular Surgery

Volumn 128, Issue 3, 2004, Pages 357-363

  Fujinaga, Kazuya ^a   Onoda, Koji ^a,b   Yamamoto, Kiyohito ^a   Imanaka Yoshida, Kyoko ^b   Takao, Motoshi ^a   Shimono, Takatsugu ^a   Shimpo, Hideto ^a   Yoshida, Toshimichi ^b   Yada, Isao ^a  

^a Dept Thorac and Cardiovasc Surg ^*  (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

16; 17; 23; 29; 33

Indexed keywords

CILOSTAZOL; CYCLIC ADENOSINE MONOPHOSPHATE PHOSPHODIESTERASE III; CYCLIC AMP PHOSPHODIESTERASE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BB; POLOXAMER; TENASCIN; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ANASTOMOSIS; ARTERY GRAFT; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; BIOLOGICAL MODEL; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; GEL; MALE; NONHUMAN; OBSERVATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; SMOOTH MUSCLE FIBER; TUNICA MEDIA; VASCULAR SURGERY;

ADMINISTRATION, TOPICAL; ANIMALS; ARTERIES; CELL DIVISION; CELLS, CULTURED; HYPERPLASIA; MALE; MUSCLE, SMOOTH; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, INBRED LEW; TENASCIN; TETRAZOLES; TUNICA INTIMA;

EID: 4444291464     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2003.11.015     Document Type: Article

References (32)

1. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s. Nature. 362:1993;801-809
2. Hosono M., Ueda M., Suehiro S., et al. Neointimal formation at the sites of anastomosis of the internal thoracic artery grafts after coronary artery bypass grafting in human subjects an immunohistochemical analysis. J Thorac Cardiovasc Surg. 120:2000;319-328
3. Sottiurai V.S., Yao J.S.T., Flinn W.R., et al. Intimal hyperplasia and neointima an ultrastructural analysis of thrombosed grafts in humans. Surgery. 93:1983;809-817
4. Clowes A.W., Gown A.M., Hanson S.R., et al. Mechanism of arterial graft failure. 1. Role of cellular proliferation in early healing of PTFE prostheses. Am J Pathol. 118:1985;43-54
5. Ogata T., Kurabayashi M., Hoshino Y., et al. Inducible expression of basic transcription element-binding protein 2 in proliferating smooth muscle cells at the vascular anastomotic stricture. J Thorac Cardiovasc Surg. 119:2000;983-989
6. Wallner K., Li C., Shah P.K., et al. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation. 99:1999;1284-1289
7. Imanaka-Yoshida K., Hiroe M., Nishikawa T., et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest. 81:2001;1015-1024
8. Imanaka-Yoshida K., Hiroe M., Yasutomi Y., et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol. 197:2002;388-394
9. Sato M., Toyozaki T., Odaka K., et al. Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation. 106:2002;1397-1402
10. Hedin J., Holm J., Hansson G.K. Induction of tenascin in rat arterial injury relationship to altered smooth muscle cell phenotype. Am J Pathol. 139:1991;649-656
11. Satta J., Soini Y., Pöllänen R., et al. Tenascin expression is associated with a chronic inflammatory process in abdominal aortic aneurysms. J Vasc Surg. 26:1997;670-675
12. Wallner K., Li C., Fishbein M.C., et al. Arterialization of human vein grafts is associated with tenascin-C expression. J Am Coll Cardiol. 34:1999;871-875
13. Imanaka-Yoshida K., Matsuura R., Isaka N., et al. Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty clinical significance of early tenascin-C expression. Virchows Archiv. 439:2001;185-190
14. LaFleur D.W., Fagin J.A., Forrester J.S., et al. Cloning and characterization of alternatively spliced isoforms of rat tenascin platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. J Biol Chem. 269:1994;20757-20763
15. LaFleur D.W., Chiang J., Fagin J.A., et al. Aortic smooth muscle cells interact with tenascin-C through its fibrinogen-like domain. J Biol Chem. 272:1997;32798-32803
16. Sharifi B.G., LaFleur D.W., Pirola C.J., et al. Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. J Biol Chem. 267:1992;23910-23915
17. Hu Y., Zou Y., Dietrich H., et al. Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation. 100:1999;861-868
18. Ishizaka N., Taguchi J., Kimura Y., et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis. 142:1999;41-46
19. Indolfi C., Avvedimento E.V., Di Lorenzo E., et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med. 3:1997;775-779
20. Kimura Y., Tani T., Kanbe T., et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforshung. 35:1985;1144-1149
21. Takahashi S., Oida K., Fujiwara R., et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20:1992;900-906
22. Tanaka T., Ishikawa T., Hagiwara M., et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology. 36:1988;313-320
23. Kusagawa H., Onoda K., Namikawa S., et al. Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer. 77:1998;98-102
24. Noda N., Minoura H., Nishiura R., et al. Expression of tenascin-C in stromal cells of the murine uterus during early pregnancy induction by interleukin-1α, prostaglandin E2, and prostaglandin F2α Biol Reprod. 63:2000;1713-1720
25. Hiatt W.R. Drug therapy medical treatment of peripheral arterial disease and claudication. N Engl J Med. 344:2001;1608-1621
26. Inoue Y., Kimura Y., Hidaka H. Role of platelets in vascular intimal hyperplasia. Jpn J Thromb Hemost. 4:1993;297
27. Ruoslahti E., Vaheri A. Cell-to-cell contact and extracellular matrix. Curr Opin Cell Biol. 9:1997;605-607
28. Cook S., McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science. 262:1993;1069-1072
29. Sevetson B.R., Kong X., Lawrence J.C. Jr. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci U S A. 90:1993;10305-10309
30. Grieco D., Porcellini A., Avvedimento E.V., et al. Requirement for cAMP-PKA pathway activation by M phase-promoting factor in the transition from mitosis to interphase. Science. 271:1996;1719-1723
31. Force T., Bonventre J.V. Growth factors and mitogen-activated protein kinases. Hypertension. 31:1998;152-161
32. Wallner K., Sharifi B.G., Shah P.K., et al. Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts. J Am Coll Cardiol. 37:2001;655-661